Guardant Health (NASDAQ:GH) Stock: Insider Musa Tariq Sells 116 Shares

Guardant Health, Inc. (NASDAQ:GH) Director Musa Tariq sold 116 shares of the business’s stock in a transaction on Friday, October 16th. The stock was sold at an average price of $165.88, for a total value of $19,242.08. Following the sale, the director owned 11,583 shares in the company, valued at approximately $1,921,388.04. The trade was a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Musa Tariq also recently made the following trade(s):

• On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $175.00, for a total value of $20,300.00.
• On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $156.45, for a total value of $18,148.20.

Guardant Health Stock Up 3.0%

NASDAQ:GH opened at $162.59 on Wednesday. The company has a market capitalization of $21.82 billion, a PE ratio of -46.59 and a beta of 1.58. Guardant Health, Inc. has a 52-week low of $66.59 and a 52-week high of $191.05. The stock has a fifty day simple moving average of $167.70 and a 200-day simple moving average of $140.50.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million during the quarter, compared to analysts’ expectations of $314.23 million. Guardant Health’s quarterly revenue was up 44.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.44) earnings per share. As a group, equities analysts anticipate that Guardant Health, Inc. will post -3.02 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GH. MCF Advisors LLC raised its holdings in Guardant Health by 755.0% in the 2nd quarter. MCF Advisors LLC now owns 171 shares of the company’s stock valued at $26,000 after acquiring an additional 151 shares during the last quarter. NFSG Corp purchased a new position in shares of Guardant Health during the 3rd quarter worth $33,000. Ascentis Independent Advisors purchased a new position in shares of Guardant Health during the 1st quarter worth $38,000. Hollencrest Capital Management acquired a new stake in shares of Guardant Health during the first quarter worth $41,000. Finally, TrinityBridge Ltd acquired a new stake in shares of Guardant Health during the second quarter worth $45,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have issued reports on GH shares. BTIG Research reaffirmed a “buy” rating and issued a $195.00 price target on shares of Guardant Health in a report on Wednesday, September 2nd. Sanford C. Bernstein reiterated an “outperform” rating and issued a $210.00 price target on shares of Guardant Health in a research report on Thursday, September 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research note on Thursday, October 15th. Evercore restated an “outperform” rating and set a $200.00 price objective on shares of Guardant Health in a research report on Monday, July 6th. Finally, Barclays lifted their price objective on Guardant Health from $200.00 to $220.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $190.00.

About Guardant Health

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company’s products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient’s response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.